Evidence map›Paper›PMID 26784009›Full record

ArticleBiomaterials2016

The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltration.

Weiwei Aileen Li, Beverly Ying Lu, Luo Gu, Youngjin Choi, Jaeyun Kim, David J Mooney

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 108 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Tailoring biomaterials for vaccine delivery.Journal of nanobiotechnology · 2024
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Vaccine adjuvants: mechanisms and platforms.Signal transduction and targeted therapy · 2023
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Review
  17. Self-adjuvanting cancer nanovaccines.Journal of nanobiotechnology · 2022
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Weiwei Aileen LiJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA; The Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Beverly Ying LuJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA; The Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Luo GuJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA; The Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Youngjin ChoiSchool of Chemical Engineering, Sungkyunkwan University, Suwon 440-746, South Korea.
Jaeyun KimSchool of Chemical Engineering, Sungkyunkwan University, Suwon 440-746, South Korea.
David J MooneyJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA; The Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA. Electronic address: mooneyd@seas.harvard.edu.
Harvard University · USSungkyunkwan University · KR

Funding

Biomaterial based breast cancer vaccineR01EB015498 · NIBIB · HARVARD MEDICAL SCHOOL · PI MOONEY, DAVID J · 2013 to 2016
$1.5M
NIBIB NIH HHS R01 EB015498
6 · The paper itself

Abstract

Biomaterial scaffold based vaccines show significant potential in generating potent antigen-specific immunity. However, the role of the scaffold surface chemistry in initiating and modulating the immune response is not well understood. In this study, a mesoporous silica micro-rod (MSR) scaffold was modified with PEG, PEG-RGD and PEG-RDG groups. PEG modification significantly enhanced BMDC activation marker up-regulation and IL-1β production in vitro, and innate immune cell infiltration in vivo. PEG-RGD MSRs and PEG-RDG MSRs displayed decreased inflammation compared to PEG MSRs, and the effect was not RGD specific. Finally, the Nlrp3 inflammasome was found to be necessary for MSR stimulated IL-1β production in vitro and played a key role in regulating immune cell infiltration in vivo. These findings suggest that simply modulating the surface chemistry of a scaffold can regulate its immune cell infiltration profile and have implications for the design and development of new material based vaccines.

Indexed as

AnimalsBone Marrow CellsCarrier ProteinsCytokinesDendritic CellsFemaleInflammasomesMice, Inbred C57BLNLR Family, Pyrin Domain-Containing 3 ProteinPorositySilicon DioxideSurface PropertiesTissue ScaffoldsCarrier ProteinsCytokinesInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseSilicon DioxideAcute inflammationInflammasomeMesoporous silicaPoly(ethylene glycol)RGD

Identifiers

PMID26784009
PMCPMC4754159
OpenAlexW2235788736

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.